Vertex Pharmaceuticals Incorporated: Difference between revisions
No edit summary |
No edit summary |
||
| Line 23: | Line 23: | ||
}} | }} | ||
Vertex Pharmaceuticals Incorporated, a leading biotechnology firm, specialises in the development and commercialization of innovative therapies for the treatment of cystic fibrosis. The company's groundbreaking products include SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO, and TRIKAFTA, all aimed at treating cystic fibrosis patients with specific mutations in their cystic fibrosis transmembrane conductance regulator gene. TRIKAFTA is particularly beneficial for patients aged 6 years and above who carry at least one F508del mutation. | |||
Vertex Pharmaceuticals Incorporated, a leading biotechnology firm, | |||
In addition to these flagship products, Vertex also has an impressive pipeline of promising treatments at various stages of clinical trials. These include VX-864, a Phase 2 clinical trial candidate for Alpha-1 Antitrypsin (AAT) deficiency, and VX-147, also in Phase 2, designed to address APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney diseases. Vertex is further investigating VX-880, a potential treatment for Type 1 Diabetes currently in Phase 1/2 trials. Moreover, VX-548, a NaV1.8 inhibitor, is under examination in Phase 2 trials for its potential to treat acute, neuropathic, and musculoskeletal pain. Lastly, the company's CTX001 is advancing through Phase 3 trials as a proposed solution for severe Sickle Cell Disease (SCD) and Thalassemia (TDT). | In addition to these flagship products, Vertex also has an impressive pipeline of promising treatments at various stages of clinical trials. These include VX-864, a Phase 2 clinical trial candidate for Alpha-1 Antitrypsin (AAT) deficiency, and VX-147, also in Phase 2, designed to address APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney diseases. Vertex is further investigating VX-880, a potential treatment for Type 1 Diabetes currently in Phase 1/2 trials. Moreover, VX-548, a NaV1.8 inhibitor, is under examination in Phase 2 trials for its potential to treat acute, neuropathic, and musculoskeletal pain. Lastly, the company's CTX001 is advancing through Phase 3 trials as a proposed solution for severe Sickle Cell Disease (SCD) and Thalassemia (TDT). | ||
Revision as of 13:55, 22 July 2023
 | |
| Type | Public company |
|---|---|
| |
| Industry | |
| Founded | 1989 |
| Headquarters | Boston, Massachusetts, U.S. |
Key people |
|
| Products | Pharmaceuticals |
| Revenue |  US$8.93 billion (2022) |
| US$4.31 billion (2022) | |
| US$3.32 billion (2022) | |
| Total assets | US$18.2 billion (2022) |
| Total equity | US$13.9 billion (2022) |
Number of employees | 4,800 (2022) |
| Website | vrtx |
| Footnotes / references [1][2] | |
Vertex Pharmaceuticals Incorporated, a leading biotechnology firm, specialises in the development and commercialization of innovative therapies for the treatment of cystic fibrosis. The company's groundbreaking products include SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO, and TRIKAFTA, all aimed at treating cystic fibrosis patients with specific mutations in their cystic fibrosis transmembrane conductance regulator gene. TRIKAFTA is particularly beneficial for patients aged 6 years and above who carry at least one F508del mutation.
In addition to these flagship products, Vertex also has an impressive pipeline of promising treatments at various stages of clinical trials. These include VX-864, a Phase 2 clinical trial candidate for Alpha-1 Antitrypsin (AAT) deficiency, and VX-147, also in Phase 2, designed to address APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney diseases. Vertex is further investigating VX-880, a potential treatment for Type 1 Diabetes currently in Phase 1/2 trials. Moreover, VX-548, a NaV1.8 inhibitor, is under examination in Phase 2 trials for its potential to treat acute, neuropathic, and musculoskeletal pain. Lastly, the company's CTX001 is advancing through Phase 3 trials as a proposed solution for severe Sickle Cell Disease (SCD) and Thalassemia (TDT).
The company primarily sells its products through specialty pharmacies and distributors in the United States, and it also maintains international distribution through specialty distributors, retail chains, hospitals, and clinics.
Vertex's research and development strategies are further enhanced by collaborations with notable industry partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem.
Since its inception in 1989, Vertex Pharmaceuticals has been at the forefront of biotechnological advancements. The company is headquartered in Boston, Massachusetts, where it continues to make strides in developing life-altering therapies.